Adjuvant Therapy for Resectable Colorectal Carcinoma With Fluorouracil Administered by Portal Vein Infusion

A Study of the Mayo Clinic and the North Central Cancer Treatment Group

Robert W. Beart, Charles G. Moertel, Harry S. Wieand, John E. Leigh, Harry E. Windschitl, Jonathan A. Van Heerden, Robert Joseph Fitzgibbons, Bruce G. Wolff

Research output: Contribution to journalArticle

97 Citations (Scopus)

Abstract

We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.

Original languageEnglish
Pages (from-to)897-901
Number of pages5
JournalArchives of Surgery
Volume125
Issue number7
DOIs
StatePublished - 1990

Fingerprint

Portal Vein
Fluorouracil
Colorectal Neoplasms
Neoplasms
Poisons
Frozen Sections
Therapeutics
Random Allocation
Catheters
Control Groups
Survival

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Adjuvant Therapy for Resectable Colorectal Carcinoma With Fluorouracil Administered by Portal Vein Infusion : A Study of the Mayo Clinic and the North Central Cancer Treatment Group. / Beart, Robert W.; Moertel, Charles G.; Wieand, Harry S.; Leigh, John E.; Windschitl, Harry E.; Van Heerden, Jonathan A.; Fitzgibbons, Robert Joseph; Wolff, Bruce G.

In: Archives of Surgery, Vol. 125, No. 7, 1990, p. 897-901.

Research output: Contribution to journalArticle

Beart, Robert W. ; Moertel, Charles G. ; Wieand, Harry S. ; Leigh, John E. ; Windschitl, Harry E. ; Van Heerden, Jonathan A. ; Fitzgibbons, Robert Joseph ; Wolff, Bruce G. / Adjuvant Therapy for Resectable Colorectal Carcinoma With Fluorouracil Administered by Portal Vein Infusion : A Study of the Mayo Clinic and the North Central Cancer Treatment Group. In: Archives of Surgery. 1990 ; Vol. 125, No. 7. pp. 897-901.
@article{661349c7f6fe459d9cfd45c68390eac9,
title = "Adjuvant Therapy for Resectable Colorectal Carcinoma With Fluorouracil Administered by Portal Vein Infusion: A Study of the Mayo Clinic and the North Central Cancer Treatment Group",
abstract = "We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2{\%}) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.",
author = "Beart, {Robert W.} and Moertel, {Charles G.} and Wieand, {Harry S.} and Leigh, {John E.} and Windschitl, {Harry E.} and {Van Heerden}, {Jonathan A.} and Fitzgibbons, {Robert Joseph} and Wolff, {Bruce G.}",
year = "1990",
doi = "10.1001/archsurg.1990.01410190095015",
language = "English",
volume = "125",
pages = "897--901",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - Adjuvant Therapy for Resectable Colorectal Carcinoma With Fluorouracil Administered by Portal Vein Infusion

T2 - A Study of the Mayo Clinic and the North Central Cancer Treatment Group

AU - Beart, Robert W.

AU - Moertel, Charles G.

AU - Wieand, Harry S.

AU - Leigh, John E.

AU - Windschitl, Harry E.

AU - Van Heerden, Jonathan A.

AU - Fitzgibbons, Robert Joseph

AU - Wolff, Bruce G.

PY - 1990

Y1 - 1990

N2 - We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.

AB - We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic reactions were mild. There was only 1 postoperative death on each study arm. At present, the median follow-up for all patients is 5.5 years (range, 1.5 to 9.5 years). Interval to progression and survival curves essentially overlap. The same lack of treatment effect is seen in both the stage B and C subsets.

UR - http://www.scopus.com/inward/record.url?scp=0025283664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025283664&partnerID=8YFLogxK

U2 - 10.1001/archsurg.1990.01410190095015

DO - 10.1001/archsurg.1990.01410190095015

M3 - Article

VL - 125

SP - 897

EP - 901

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 7

ER -